Public health research and advocacy, not mutually exclusive

My public health colleague, Adam Finkel, ScD, MPP, received this month the 2013 Alumni Leadership award from the Harvard School of Public Health (HSPH), as part of the school’s 100th birthday celebration. Finkel and I were co-workers in the mid-1990’s at the Occupational Safety and Health Administration, where he was the Director of the Office of Health Standards. I learned more from him about risk analysis and risk assessment than in any semester–long course. Why? Because agency risk assessments are not academic exercises when they are used to inform regulatory decisions.

Finkel touched on this point in his remarks upon accepting the award.  He explained:

“At the HSPH celebration last week, one of the faculty, approvingly, but maybe a tad patronizingly, referred to me as a HSPH graduate who has decided to ‘go into advocacy.’”

Finkel shared his reaction to the remark with the assembled audience:

“I think you can do worse than be an advocate---you can actually have no values--- but worse still, you can advocate obliviously while contenting yourself you are ‘neutral.’ I often end my first class in environmental science or law with two quotations: (1) ‘Policy makers should base their decisions about most health risks on the expected value of the risk, not the upper bound.’ [That’s from two economists Finkel studied under at the Kennedy School of Government]; and (2) ‘Verily I say unto you, inasmuch as ye have done it unto one of the least of these my brethren, ye have done it unto me.’” I know what value system I prefer, but I will never tire of reminding people that if you chose the first, you are also an advocate for a particular set of values.”

He also remarked about his unflagging support for risk and cost-benefit analyses, but not for their own sake:

“I think we need scientific and economic analyses to do much more than help us understand, but rather to identify bold policies and highlight ones that do more than push the rock up the hill ad infinitum. To give one example, perhaps HSPH should leave it to others to dissect which endocrine disruptor is the least bad ingredient to use in plastic water bottles, and ask instead how we can help return the market to the day when Americans weren’t trucking 9 billion bottles of water (it falls from the sky, I’m told!) to and fro every year, and throwing most of them into the ground soon after using them.."

Today our public health agencies, such as EPA and OSHA, are hampered by officials inside and outside the Administration from proposing much-needed health protections. The demands for new and more risk assessments of questionable value are largely delay tactics used for political and the economic interests of the powerful. Our nation and world, in particular our workers and our children, would benefit greatly if policymakers took Finkel’s recommendations to heart.

More like this

Over the next week, two Senate committees will hold confirmation hearings on senior Administration officials who could play key roles in worker health and safety policy.  First, the Senate HELP Committee will meet tomorrow (May 7) to consider the nomination of M. Patricia Smith for Solicitor of…
In 1971 under the National Cancer Act, Congresss authorized the 3-person President's Cancer Panel which is charged with monitoring the "development and execution of the National Cancer Program" and preparing periodic progress reports for the President.  Over the years, the Panel has examined…
The Washington Post reported yesterday that President-elect Obama wants Harvard law professor Cass R. Sunstein to serve as the head of OMB's Office of Information and Regulatory Affairs ( OIRA).   I'm not prepared at this point to tangle intellectually with a  magna cum laude graduate of …
The Union of Concerned Scientists (UCS) filed an amicus brief in support of a lawsuit against one of President Trump’s deregulatory efforts. Executive Order 13771 (EO) requires an agency to rescind two regulations for each one it wants to adopt, and have the action's combined incremental costs…